IFG Advisory’s Adaptimmune Therapeutics ADAP Stock Holding History

IFG Advisory’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,725	Closed	-$1.52K	–	751
2025 Q3	$1.52K	Hold	11,725	–	–	﹤0.01%	763
2025 Q2	$2.81K	Buy	11,725 +1,725	+17%	+$460	﹤0.01%	737
2025 Q1	$1.97K	Buy	+10,000	New	+$5.18K	﹤0.01%	675
2024 Q4	–	Sell	-27,500	Closed	-$26.1K	–	673
2024 Q3	$26.1K	Buy	+27,500	New	+$31.2K	﹤0.01%	384

Other funds holding ADAP

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

IFG Advisory's ADAP Position: Q4 2025 in Review

IFG Advisory sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 11,725 shares — an estimated $1.52K sold.

IFG Advisory first reported a position in ADAP in Q3 2024 and held it in 4 quarters. The position peaked at $26.1K in Q3 2024. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

IFG Advisory reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
IFG Advisory sold 11,725 Adaptimmune Therapeutics shares in Q4 2025, an estimated $1.52K.
IFG Advisory first reported a position in Adaptimmune Therapeutics in Q3 2024 and held it in 4 quarters.
IFG Advisory's Adaptimmune Therapeutics position peaked at $26.1K in Q3 2024.
10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on IFG Advisory's 13F filing for Q4 2025, filed 10 Feb 2026.